Ligand-based pharmacophore modeling and Bayesian approaches to identify c-Src inhibitors

References

• Cohen P. Protein kinases – the major drug targets of the twenty-first century. Nat Rev Drug Discov 2002;1:309–15
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355–65
   PubMed Web of Science ®Google Scholar
• Michael Bradshaw J. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal 2010;22:1175–84
   PubMedGoogle Scholar
• Sadowski I, Stone JC, Pawson T. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol 1986;6:4396–408
   PubMed Web of Science ®Google Scholar
• Mayer BJ, Hamaguchi M, Hanafusa H. A novel viral oncogene with structural similarity to phospholipase C. Nature 1988;332:272–5
   PubMed Web of Science ®Google Scholar
• Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997;385:595–602
   PubMed Web of Science ®Google Scholar
• Banibrata S, Faye MJ. Regulation of Src family kinases in human cancers. J Signal Transduct 2011;2011:1–14
   Google Scholar
• Pan Q, Qiao F, Gao C, et al. Cdk5 targets active Src for ubiquitin-dependent degradation by phosphorylating Src (S75). Cell Mol Life Sci 2011;68:3425--36
   Google Scholar
• Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997;385:602–9
   PubMed Web of Science ®Google Scholar
• Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2:467–75
   PubMed Web of Science ®Google Scholar
• Margaret CF. Src in cancer: Deregulation and consequences for cell behaviour. Biochim Biophys Acta Rev Cancer 2002;1602:114–30
   Google Scholar
• Courtneidge SA. Role of Src in signal transduction pathways. Biochem Soc Trans 2002;30:11–17
   PubMedGoogle Scholar
• Kraker AJ, Hartl BG, Amar AM, et al. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharm 2000;60:885–98
   PubMed Web of Science ®Google Scholar
• Blake RA, Broome MA, Liu X, et al. SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cel Biol 2000;20:9018–27
   PubMed Web of Science ®Google Scholar
• Wang YD, Miller K, Boschelli DH, et al. Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bio Med Chem Lett 2000;10:2477–80
   PubMed Web of Science ®Google Scholar
• Berger D, Dutia M, Powell D, et al. Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors. Bio Med Chem Lett 2002;12:2989–92
   PubMedGoogle Scholar
• Boschelli DH, Wang DY, Ye F, et al. Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles. Bioorg Med Chem Lett 2002;12:2011–14
   PubMedGoogle Scholar
• MacKerell AD, Brooks CL, Nilsson L, et al. CHARMM: the energy function and its parameterization with an overview of the program. In: Schleyer PVR, ed. The encyclopedia of computational chemistry, Vol. 1. Chichester: John Wiley & Sons; 1998:271–7
   Google Scholar
• Brooks B, Bruccoleri R, Olafson B, et al. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983;4:187–217
   Web of Science ®Google Scholar
• Sakkiah S, Thangapandian S, John S, et al. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Eur J Med Chem 2010;45:2132–40
   PubMed Web of Science ®Google Scholar
• Sakkiah S, Baek A, Lee KW. Pharmacophore modeling and molecular dynamics simulation to identify the critical chemical features against human sirtuin2 inhibitors. J Mol Stru 2012;1011:66–75
   Web of Science ®Google Scholar
• Debnath AK. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. J Med Chem 2003;46:4501–15
   PubMed Web of Science ®Google Scholar
• Lu IL, Tsai KC, Chiang YK, et al. A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem 2008;43:1603–11
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. 2004. Available from: http://cactus.nci.nih.gov/download/nci [last accessed 31 Jan 2013]
   Google Scholar
• Maybridge Chemical Company Ltd. Maybridge Chemical Database. Available from: http://www.maybridge.com
   Google Scholar
• Chembridge. Available from: http://chembridge.com
   Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3–25
   Web of Science ®Google Scholar
• Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 2003;21:289–307
   PubMed Web of Science ®Google Scholar
• Sakkiah S, Thangapandian S, John S, Lee KW. Identification of critical chemical features for Aurora kinase-B inhibitors using Hip-Hop, virtual screening and molecular docking. J Mol Struct 2011;985:14–26
   Web of Science ®Google Scholar
• Dalgarno D, Stehle T, Narula S, et al. Structural basis of src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Chem Biol Drug Des 2006;67:46–57
   PubMed Web of Science ®Google Scholar
• Gehlhaar DK, Verkhivker GM, Rejto PA, et al. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem Biol 1995;2:317–24
   PubMed Web of Science ®Google Scholar
• Muegge I. PMF scoring revisited. J Med Chem 2005;49:5895–902
   Google Scholar
• Jain AN. Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities. J Comput Aided Mol Des 1996;10:427–40
   PubMed Web of Science ®Google Scholar
• Krammer A, Kirchhoff PD, Jiang X, et al. LigScore: a novel scoring function for predicting binding affinities. J Mol Graph Model 2005;23:395–407
   PubMed Web of Science ®Google Scholar
• Böhm HJ. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 1992;6:61–78
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: A new approach for rapid, accurate docking and scoring. 1: method and assessment of docking accuracy. J Med Chem 2004;47:1739–49
   PubMed Web of Science ®Google Scholar
• Glick M, Jenkins JL, Nettles JH, et al. Enrichment of high-throughput screening data with increasing levels of noise using support vector machines, recursive partitioning, and Laplacian-modified naive Bayesian classifiers. J Chem Inf Model 2005;46:193–200
   Google Scholar
• Gelman A, Carlin JB, Stern HS. Bayesian model analysis. 3rd ed. London: Chapman & Hall; 2003
   Google Scholar
• Thangapandian S, John S, Sakkiah S, Lee KW. Pharmacophore-based virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors. Eur J Med Chem 2011;46:1593–603
   PubMed Web of Science ®Google Scholar
• Oberdoerffer P, Michan S, McVay M., et al. SIRT1 Redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008;135:907–18
   PubMed Web of Science ®Google Scholar
• Imai Si, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000;403:795–800
   PubMed Web of Science ®Google Scholar
• Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 2011;39:W270–7
   PubMed Web of Science ®Google Scholar
• Triballeau N, Acher F, Brabet I, et al. Virtual screening workflow development guided by the “Receiver Operating Characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 2005;48:2534–47
   PubMed Web of Science ®Google Scholar